Comparison of Cox’s Regression Model and Weibull’ Parametric Model in Evaluating Factors Affecting in First Recurrence of Epithelial Ovarian Cancer

  • Kourosh Sayehmiri Mail Biostatistics department, health faculty
Keywords:
ovarian cancer, recurrence, predictor, Cox regression, Weibull parametric method

Abstract

Ovarian cancer is one of the most deadly women's gynecological malignancies in the world, and despite the low prevalence, it accounts for about 5% of all cancer deaths in women. Survival analysis is a regression relationship between a set of variables with a specific outcome, which is considered disease survival or recurrence in medical studies. The aim of this study is to determine the important factors in the first recurrence of patients with epithelial ovarian cancer with two statistics methods. In this study, we review medical records of patients with epithelial ovarian cancer who referred to the oncology and radiotherapy department of Imam Hossein Hospital of Tehran from the beginning of 2007 to the end of 2018. Univariate and multivariate Cox regression, as well as the parametric Weibull method, were used to investigate the factors affecting patients' first recurrence. We perform all calculations with Stata Ver14. Of the 141 patients, 58 patients (41%) had a first recurrence during our follow-up. The mean time to the first recurrence was 24.88 months. Univariate Cox regression and univariate Weibull analysis showed that metastatic tumor and tumor stage had highly significant effects in the first recurrence of epithelial ovarian cancer. In multivariate Cox and multivariate Weibull analysis, the metastatic tumor had a significant effect in the first recurrence of epithelial ovarian cancer. One of the causes of ovarian cancer recurrence may be diagnosis happened at late stages. Therefore, screening programs are needed to reduce illness and death from ovarian cancer.

References

1. Lindemann K, Beale PJ, Rossi E, Goh JC, Vaughan MM, Tenney ME, et al. Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103). Cancer chemotherapy and pharmacology. 2019;83(1):97-105.
2. Marchetti C, Kristeleit R, McCormack M, Mould T, Olaitan A, Widschwendter M, et al. Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review. Gynecologic oncology. 2017;144(1):57-60.
3. Clarke CL, Kushi LH, Chubak J, Pawloski PA, Bulkley JE, Epstein MM, et al. Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients. Cancer Epidemiology and Prevention Biomarkers. 2019;28(5):996-9.
4. Sun Y, Liu S, Feng Z, Cheng J, Lu L, Wang M, et al. Preoperative omental metastasis-related maximum standardized fluorine-18-fluorodeoxyglucose uptake value can predict chemosensitivity and recurrence in advanced high-grade serous ovarian cancer patients. Nuclear medicine communications. 2018;39(8):761-7.
5. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA: a cancer journal for clinicians. 2018;68(4):284-96.
6. Shimizu A, Sawada K, Kimura T. Development of novel approaches to detect ovarian cancer recurrence. Journal of Medical Artificial Intelligence. 2019;2.
7. Li Z, Hong N, Robertson M, Wang C, Jiang G. Preoperative red cell distribution width and neutrophil-to-lymphocyte ratio predict survival in patients with epithelial ovarian cancer. Scientific reports. 2017;7:43001.
8. Omurlu IK, Ture M, Tokatli F. The comparisons of random survival forests and Cox regression analysis with simulation and an application related to breast cancer. Expert Systems with Applications. 2009;36(4):8582-8.
9. Zheng Q-Q, Wang P, Hui R, Yao A-M. Prognostic analysis of ovarian cancer patients using the Cox regression model. Chinese Journal of Cancer. 2009;28(2):170-2.
10. Mysona D, Pyrzak A, Purohit S, Zhi W, Sharma A, Tran L, et al. A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer. Gynecologic oncology. 2019;152(3):574-80.
11. Nie D, Gong H, Mao X, Li Z. Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: A retrospective study. Gynecol Oncol. 2019;152(2):259-64.
12. Previs R, Bevis K, Huh W, Tillmanns T, Perry L, Moore K, et al. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. Gynecologic oncology. 2014;132(3):531-6.
13. Luvero D, Plotti F, Montera R, Terranova C, De Cicco NC, Scaletta G, et al. Ovarian cancer relapse: From the latest scientific evidence to the best practice. Critical reviews in oncology/hematology. 2019.
14. Shinagare AB, Balthazar P, Ip IK, Lacson R, Liu J, Ramaiya N, et al. High-Grade Serous Ovarian Cancer: Use of Machine Learning to Predict Abdominopelvic Recurrence on CT on the Basis of Serial Cancer Antigen 125 Levels. Journal of the American College of Radiology. 2018;15(8):1133-8.
15. Nagle C, Dixon S, Jensen A, Kjaer S, Modugno F, DeFazio A, et al. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. British journal of cancer. 2015;113(5):817.
16. Tran A-Q, Cohen JG, Li AJ. Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer. Gynecologic oncology. 2015;138(2):263-6.
17. Zhang M, Xie X, Lee AH, Binns CW, Holman CAJ. Body mass index in relation to ovarian cancer survival. Cancer Epidemiology and Prevention Biomarkers. 2005;14(5):1307-10.
Published
2020-11-19
How to Cite
1.
Sayehmiri K. Comparison of Cox’s Regression Model and Weibull’ Parametric Model in Evaluating Factors Affecting in First Recurrence of Epithelial Ovarian Cancer. Acta Med Iran. 58(9):445-451.
Section
Articles